Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Whitepaper

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

Bromodomain and extra-terminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes.

BET proteins bind acetylated histone tails via their bromodomain, bringing the elongation complex to the promoter region. OTX015 specifically binds to BRD2, BRD3 and BRD4 to prevent BET proteins from binding to chromatin, inhibiting gene transcription.

OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells, in vitro and in vivo. OTD Therapeutic Development aimed to establish the recommended dose of OTX-15 in patients with haematological malignancies.

Download this report to find out the results of patients with acute leukaemia, including study methods, findings and interpretation.

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

For Free, instant access, click below.

Download Whitepaper

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.




Thank You

Your white paper is now downloading... Click here if the download does not begin.

Go Top